RSH is looking at developing another product which isn't an extension of wheezo but "complement" it.....what did I tell you guys when about the failed T/O bid for a company with a MC of only $26M.
"Company continues to be on track with the development of its wearable medical device, Sorfe, and international Key Opinion Leader (KOL) interest in the project remains high. A tested device ready for clinical validation will be available in late March/early April. This device is designed to monitor nocturnal asthma and also a completely new vertical in exercise induced asthma in the lucrative sports industry, which is a large untapped opportunity. Simple effective solutions do not exist for these conditions today. This technology will complement wheezo® which is designed for ambulatory “daytime” monitoring."
RSH Price at posting:
4.7¢ Sentiment: Hold Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)